Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350

1.

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis.

Forrester S, Siefert K, Ashwin H, Brown N, Zelmar A, James S, Lagos D, Timmis J, Chatterjee M, Mottram JC, Croft SL, Kaye PM.

Wellcome Open Res. 2019 Dec 10;4:198. doi: 10.12688/wellcomeopenres.15606.1. eCollection 2019.

2.

Activity of chitosan and its derivatives against Leishmania major and L. mexicana in vitro.

Riezk A, Raynes JG, Yardley V, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01772-19. doi: 10.1128/AAC.01772-19. [Epub ahead of print]

3.

Using species distribution models to predict potential hot-spots for Rift Valley Fever establishment in the United Kingdom.

Simons RRL, Croft S, Rees E, Tearne O, Arnold ME, Johnson N.

PLoS One. 2019 Dec 23;14(12):e0225250. doi: 10.1371/journal.pone.0225250. eCollection 2019.

4.

An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture.

Clark DJ, Moore CM, Flanagan M, Bocxlaer KV, Piperaki ET, Yardley V, Croft SL, Tyson J, Whitehouse SP, O'Halloran J, Krishna S, Staines HM.

Biotechniques. 2020 Feb;68(2):79-84. doi: 10.2144/btn-2019-0086. Epub 2019 Nov 27.

5.

Linking global drivers of agricultural trade to on-the-ground impacts on biodiversity.

Green JMH, Croft SA, Durán AP, Balmford AP, Burgess ND, Fick S, Gardner TA, Godar J, Suavet C, Virah-Sawmy M, Young LE, West CD.

Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):23202-23208. doi: 10.1073/pnas.1905618116. Epub 2019 Oct 28. Erratum in: Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):26085-26086.

6.

Innovations for the elimination and control of visceral leishmaniasis.

Selvapandiyan A, Croft SL, Rijal S, Nakhasi HL, Ganguly NK.

PLoS Negl Trop Dis. 2019 Sep 19;13(9):e0007616. doi: 10.1371/journal.pntd.0007616. eCollection 2019 Sep. No abstract available.

7.

Modeling current and potential distributions of mammal species using presence-only data: A case study on British deer.

Croft S, Ward AI, Aegerter JN, Smith GC.

Ecol Evol. 2019 Jul 11;9(15):8724-8735. doi: 10.1002/ece3.5424. eCollection 2019 Aug.

8.

Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.

Wong YC, Croft S, Smith SA, Lin LCW, Cukalac T, La Gruta NL, Drexler I, Tscharke DC.

J Virol. 2019 Oct 15;93(21). pii: e01154-19. doi: 10.1128/JVI.01154-19. Print 2019 Nov 1.

9.

Exploring the characteristics, acuity and management of adult ED patients at night-time.

Simpson R, Croft S, O'Keeffe C, Jacques R, Stone T, Ahmed N, Mason SM.

Emerg Med J. 2019 Sep;36(9):554-557. doi: 10.1136/emermed-2018-208248. Epub 2019 Jul 30.

10.

Development of an in vitro media perfusion model of Leishmania major macrophage infection.

O'Keeffe A, Hyndman L, McGinty S, Riezk A, Murdan S, Croft SL.

PLoS One. 2019 Jul 24;14(7):e0219985. doi: 10.1371/journal.pone.0219985. eCollection 2019.

11.

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P, Croft SL.

Int J Parasitol Drugs Drug Resist. 2019 Dec;11:106-117. doi: 10.1016/j.ijpddr.2019.06.003. Epub 2019 Jun 20. Review.

12.

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.

Wijnant GJ, Croft SL, de la Flor R, Alavijeh M, Yardley V, Braillard S, Mowbray C, Van Bocxlaer K.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00829-19. doi: 10.1128/AAC.00829-19. Print 2019 Sep.

13.

The risk of foot-and-mouth disease becoming endemic in a wildlife host is driven by spatial extent rather than density.

Croft S, Aegerter JN, Massei G, Smith GC.

PLoS One. 2019 Jun 26;14(6):e0218898. doi: 10.1371/journal.pone.0218898. eCollection 2019.

14.

Science-based wildlife disease response.

Vicente J, Apollonio M, Blanco-Aguiar JA, Borowik T, Brivio F, Casaer J, Croft S, Ericsson G, Ferroglio E, Gavier-Widen D, Gortázar C, Jansen PA, Keuling O, Kowalczyk R, Petrovic K, Plhal R, Podgórski T, Sange M, Scandura M, Schmidt K, Smith GC, Soriguer R, Thulke HH, Zanet S, Acevedo P.

Science. 2019 Jun 7;364(6444):943-944. doi: 10.1126/science.aax4310. No abstract available.

PMID:
31171687
15.

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.

Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL.

Int J Parasitol Drugs Drug Resist. 2019 Dec;11:129-138. doi: 10.1016/j.ijpddr.2019.02.002. Epub 2019 Feb 26.

16.

Leishmaniasis - Authors' reply.

Burza S, Croft SL, Boelaert M.

Lancet. 2019 Mar 2;393(10174):872-873. doi: 10.1016/S0140-6736(18)33057-5. No abstract available.

PMID:
30837140
17.

Characterizing laser-plasma ion accelerators driving an intense neutron beam via nuclear signatures.

Favalli A, Guler N, Henzlova D, Croft S, Falk K, Gautier DC, Ianakiev KD, Iliev M, Palaniyappan S, Roth M, Fernandez JC, Swinhoe MT.

Sci Rep. 2019 Feb 14;9(1):2004. doi: 10.1038/s41598-019-39054-z.

18.

Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis.

Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S, James S, Lagos D, Timmis J, Mottram JC, Croft SL, Kaye PM.

Version 2. Wellcome Open Res. 2019 Jan 2 [revised 2019 Jan 1];3:135. doi: 10.12688/wellcomeopenres.14867.2. eCollection 2018.

19.

Comparison of Pharmacist-Directed Management of Multiplex PCR Blood Culture Results with Conventional Microbiology Methods on Effective and Optimal Therapy within a Community Hospital.

Porter AM, Bland CM, Young HN, Allen DR, Croft SR, Gayheart RE, Miller PW, Musgrove RJ, Robertson EM, Gibson GM.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01575-18. doi: 10.1128/AAC.01575-18. Print 2019 Jan.

20.

Urgent care axis for the older adult: where is best to target interventions?

Bunn JG, Croft SJ, O'Keeffe C, Jacques RM, Simpson RM, Stone T, Conroy SP, Mason SM.

Emerg Med J. 2019 Jan;36(1):22-26. doi: 10.1136/emermed-2018-207505. Epub 2018 Sep 3.

21.

Defect generation in TiO2 nanotube anodes via heat treatment in various atmospheres for lithium-ion batteries.

Savva AI, Smith KA, Lawson M, Croft SR, Weltner AE, Jones CD, Bull H, Simmonds PJ, Li L, Xiong H.

Phys Chem Chem Phys. 2018 Sep 12;20(35):22537-22546. doi: 10.1039/c8cp04368j.

PMID:
30140842
22.

Leishmaniasis.

Burza S, Croft SL, Boelaert M.

Lancet. 2018 Sep 15;392(10151):951-970. doi: 10.1016/S0140-6736(18)31204-2. Epub 2018 Aug 17. Review.

PMID:
30126638
23.

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.

Wijnant GJ, Van Bocxlaer K, Fortes Francisco A, Yardley V, Harris A, Alavijeh M, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00631-18. doi: 10.1128/AAC.00631-18. Print 2018 Oct.

24.

Evaluating European Food Safety Authority Protection Goals for Honeybees (Apis mellifera): What Do They Mean for Pollination?

Croft S, Brown M, Wilkins S, Hart A, Smith GC.

Integr Environ Assess Manag. 2018 Nov;14(6):750-758. doi: 10.1002/ieam.4078. Epub 2018 Aug 3.

PMID:
29923683
25.

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Alavijeh M, Silva-Pedrosa R, Antunes S, Mauricio I, Murdan S, Croft SL.

Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):223-228. doi: 10.1016/j.ijpddr.2018.04.001. Epub 2018 Apr 12.

26.

Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.

27.

Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.

Voak AA, Standing JF, Sepúlveda N, Harris A, Croft SL, Seifert K.

J Antimicrob Chemother. 2018 May 1;73(5):1314-1323. doi: 10.1093/jac/dky014.

28.

Human Rhinovirus 3C protease cleaves RIPK1, concurrent with caspase 8 activation.

Croft SN, Walker EJ, Ghildyal R.

Sci Rep. 2018 Jan 25;8(1):1569. doi: 10.1038/s41598-018-19839-4.

29.

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02009-17. doi: 10.1128/AAC.02009-17. Print 2018 Mar.

30.

In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.

Basilico N, Parapini S, Sparatore A, Romeo S, Misiano P, Vivas L, Yardley V, Croft SL, Habluetzel A, Lucantoni L, Renia L, Russell B, Suwanarusk R, Nosten F, Dondio G, Bigogno C, Jabes D, Taramelli D.

Molecules. 2017 Dec 1;22(12). pii: E2102. doi: 10.3390/molecules22122102.

31.

Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.

Croft SL.

Parasitology. 2018 Feb;145(2):237-247. doi: 10.1017/S0031182017001664. Epub 2017 Oct 6. Review.

32.

Picornaviruses and Apoptosis: Subversion of Cell Death.

Croft SN, Walker EJ, Ghildyal R.

mBio. 2017 Sep 19;8(5). pii: e01009-17. doi: 10.1128/mBio.01009-17. Review.

33.

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.

Baker DA, Stewart LB, Large JM, Bowyer PW, Ansell KH, Jiménez-Díaz MB, El Bakkouri M, Birchall K, Dechering KJ, Bouloc NS, Coombs PJ, Whalley D, Harding DJ, Smiljanic-Hurley E, Wheldon MC, Walker EM, Dessens JT, Lafuente MJ, Sanz LM, Gamo FJ, Ferrer SB, Hui R, Bousema T, Angulo-Barturén I, Merritt AT, Croft SL, Gutteridge WE, Kettleborough CA, Osborne SA.

Nat Commun. 2017 Sep 5;8(1):430. doi: 10.1038/s41467-017-00572-x.

34.

A systematic approach to estimate the distribution and total abundance of British mammals.

Croft S, Chauvenet ALM, Smith GC.

PLoS One. 2017 Jun 28;12(6):e0176339. doi: 10.1371/journal.pone.0176339. eCollection 2017.

35.

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.

Voak AA, Harris A, Qaiser Z, Croft SL, Seifert K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00497-17. doi: 10.1128/AAC.00497-17. Print 2017 Sep.

36.

Association of Ankle Arthritis Score With Need for Revision Surgery.

Croft S, Wing KJ, Daniels TR, Glazebrook M, Dryden P, Younger A, Penner MJ, Sutherland JM.

Foot Ankle Int. 2017 Sep;38(9):939-943. doi: 10.1177/1071100717712891. Epub 2017 Jun 15.

PMID:
28617095
37.

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00358-17. doi: 10.1128/AAC.00358-17. Print 2017 Aug.

38.

Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.

Burrell-Saward H, Harris AJ, de LaFlor R, Sallam H, Alavijeh MS, Ward TH, Croft SL.

Int J Antimicrob Agents. 2017 Aug;50(2):203-209. doi: 10.1016/j.ijantimicag.2017.01.038. Epub 2017 May 25.

39.

What is the evidence for the management of patients along the pathway from the emergency department to acute admission to reduce unplanned attendance and admission? An evidence synthesis.

Credé SH, O'Keeffe C, Mason S, Sutton A, Howe E, Croft SJ, Whiteside M.

BMC Health Serv Res. 2017 May 16;17(1):355. doi: 10.1186/s12913-017-2299-8. Review.

40.

Design of treatments for cutaneous and visceral leishmaniasis.

Croft S.

Nihon Yakurigaku Zasshi. 2017;149(5):220-224. doi: 10.1254/fpj.149.220. Japanese. No abstract available.

PMID:
28484104
41.

Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.

Daunes S, Yardley V, Croft SL, D'Silva C.

Bioorg Med Chem. 2017 Feb 15;25(4):1329-1340. doi: 10.1016/j.bmc.2016.12.016. Epub 2016 Dec 18.

42.

Evaluating drug resistance in visceral leishmaniasis: the challenges.

Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L.

Parasitology. 2018 Apr;145(4):453-463. doi: 10.1017/S0031182016002031. Epub 2016 Nov 21. Review.

43.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity).

Richards S, Amaravadi L, Pillutla R, Birnboeck H, Torri A, Cowan KJ, Papadimitriou A, Garofolo F, Satterwhite C, Piccoli S, Wu B, Krinos-Fiorotti C, Allinson J, Berisha F, Cocea L, Croft S, Fraser S, Galliccia F, Gorovits B, Gupta S, Gupta V, Haidar S, Hottenstein C, Ishii-Watabe A, Jani D, Kadavil J, Kamerud J, Kramer D, Litwin V, Lima Santos GM, Nelson R, Ni Y, Pedras-Vasconcelos J, Qiu Y, Rhyne P, Safavi A, Saito Y, Savoie N, Scheibner K, Schick E, Siguenza PY, Smeraglia J, Staack RF, Subramanyam M, Sumner G, Thway T, Uhlinger D, Ullmann M, Vitaliti A, Welink J, Whiting CC, Xue L, Zeng R.

Bioanalysis. 2016 Dec;8(23):2475-2496.

44.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies).

Song A, Lee A, Garofolo F, Kaur S, Duggan J, Evans C, Palandra J, Donato LD, Xu K, Bauer R, Bustard M, Chen L, Cocea L, Croft S, Galliccia F, Haidar S, Hughes N, Ishii-Watabe A, Islam R, Jones B, Kadavil J, Krantz C, Lima Santos GM, Olah T, Pedras-Vasconcelos J, Staelens L, Saito Y, Savoie N, Scheibner K, Spitz S, Tampal N, Thomas E, Vinter S, Wakelin-Smith J, Welink J, Zeng J, Zhou S.

Bioanalysis. 2016 Dec;8(23):2457-2474.

45.

Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.

Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, Ramos-Rodriguez JJ, Pitstick R, Wegmann S, Garcia-Alloza M, Carlson GA, Hyman BT, Spires-Jones TL.

Eur J Neurosci. 2016 Dec;44(12):3056-3066. doi: 10.1111/ejn.13442. Epub 2016 Nov 12.

46.

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 - small molecules, peptides and small molecule biomarkers by LCMS).

Yang E, Welink J, Cape S, Woolf E, Sydor J, James C, Goykhman D, Arnold M, Addock N, Bauer R, Buonarati M, Ciccimaro E, Dodda R, Evans C, Garofolo F, Hughes N, Islam R, Nehls C, Wilson A, Briscoe C, Bustard M, Coppola L, Croft S, Drexler D, Ferrari L, Fraier D, Jenkins R, Kadavil J, King L, Li W, Lima Santos GM, Musuku A, Ramanathan R, Saito Y, Savoie N, Summerfield S, Sun R, Tampal N, Vinter S, Wakelin-Smith J, Yue Q.

Bioanalysis. 2016 Nov;8(22):2363-2378. doi: 10.4155/bio-2016-4992. Epub 2016 Oct 7.

47.

Rhinovirus 16 2A Protease Affects Nuclear Localization of 3CD during Infection.

Walker E, Jensen L, Croft S, Wei K, Fulcher AJ, Jans DA, Ghildyal R.

J Virol. 2016 Nov 28;90(24):11032-11042. Print 2016 Dec 15.

48.

Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

J Pharm Pharmacol. 2016 Jul;68(7):862-72. doi: 10.1111/jphp.12548. Epub 2016 May 27.

49.

China-Africa and China-Asia Collaboration on Schistosomiasis Control: A SWOT Analysis.

Xu J, Bergquist R, Qian YJ, Wang Q, Yu Q, Peeling R, Croft S, Guo JG, Zhou XN.

Adv Parasitol. 2016;92:435-66. doi: 10.1016/bs.apar.2016.02.005. Epub 2016 Apr 7. Review.

PMID:
27137455
50.

A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Tegazzini D, Díaz R, Aguilar F, Peña I, Presa JL, Yardley V, Martin JJ, Coteron JM, Croft SL, Cantizani J.

Antimicrob Agents Chemother. 2016 May 23;60(6):3524-32. doi: 10.1128/AAC.01781-15. Print 2016 Jun.

Supplemental Content

Support Center